Research programme: hepatitis B therapeutics - Chromis Therapeutics

Drug Profile

Research programme: hepatitis B therapeutics - Chromis Therapeutics

Alternative Names: CHR-101

Latest Information Update: 01 Mar 2016

Price : $50

At a glance

  • Originator Chromis Therapeutics
  • Class Small molecules
  • Mechanism of Action Capsid protein inhibitors; Viral core protein inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 25 Feb 2016 Preclinical development in Hepatitis B in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top